What practices should know now about preparing for psychedelic treatment delivery
FDA approval of psychedelic therapies is on the horizon. Compass Pathways' COMP360 has two positive Phase 3 trials and recently received an FDA Priority Review designation, putting potential approval on a compressed timeline.
Start thinking about preparing now
You likely have questions on: how to staff these treatments, how to select the right patients, how the care model will work (setting of care, rooming, group versus individual formats, and scalability), and whether the model will be financially sustainable. You're not alone. Compass Pathways and Osmind are actively building the resources.
SPRAVATO® (esketamine) experience gives you a head start, but it's not a prerequisite
If you've offered SPRAVATO®, procurement, REMS, and financial support pathways will feel directionally similar. But practices that skipped SPRAVATO® or found it hard to implement shouldn't count themselves out.
Operations and care models will look different from SPRAVATO®
Staffing, session length, room setup, and patient selection all require a distinct approach from SPRAVATO®. You'll need to consider rooms, retreatment protocols, and group versus individual formats.
Reimbursement answers are on the way
Acquisition cost and payer coverage are the biggest open questions right now. Expect more clarity in the months ahead.
You don't have to figure this out alone
Osmind and Compass Pathways are collaborating specifically to inform how small-to-medium-sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved.
You're closer to ready than you think.
Get priority access to psychedelic treatment readiness resources. Scan below to get started.
You'll also get access to The Psychiatry Collective, where clinicians preparing for this next wave are already gathering. If you're thinking about COMP360 readiness, this is the community that gets you there faster.
Join 1,000+ forward-thinking clinicians at
psychiatrycollective.com